A method of treating human erythrocytes with trypsin has been modified and found to be an efficient and practical indicator system for the rubella hemagglutination-inhibition test. Both the trypsin-treated human cells and the widely used, newborn chicken erythrocytes were used in comparative testing of 464 selected diagnostic rubella serums. Results with each cell system were essentially the same. The trypsin treatment procedure has been found to be relatively simple, and with our limited testing has not presented any problems with reproducibility. Other advantages include the ready availability of human cells, greater intralaboratory standardization of the test by using the same donors over a long period of time, and elimination of adsorption of test sera with red blood cells.
Since the introduction of the rubella hemagglutination-inhibition test in 1967 (9) , erythrocytes of several animal species, primarily avian, have been recommended for use in the test (4, 6, 9) . The most commonly employed have been cells from newly hatched chickens. These cells can be used for only a period of 2 weeks after collection. Laboratories desiring to offer the test on routine basis must, therefore, either purchase cells or make some arrangement to have newly hatched chickens available on a regular weekly or biweekly schedule. Many small laboratories, with little initial demand for the test, find this economically impractical.
One commercial laboratory, Abbott Diagnostic Laboratories, has for some time been marketing stabilized avian cells, with a usable life of 60 days. A method for the production of stable, formalinized sheep cells has been published (3) . The stabilized avian cells are only available commercially, and the sheep cell technique is quite time consuming.
In 1971, Biddle (1) reported the use of trypsinized human cells in rubella hemagglutination and hemagglutination-inhibitiom. The ready availability of human cells to all laboratories would make their use preferable to those cell systems currently available. This paper reports our experience in applying human cells to routine rubella testing and our modification of this reported technique.
MATERIALS AND METHODS
Alsever's solution, dextrose-gelatin-Veronal (DGV) buffer, 5.0% dextran SO4, 1.0 M calcium chloride, and N-2-hydroxyethylpiperazine-N'-2'-ethanesulfonic acid (HEPES)-saline-albumin-gelatin (HSAG) buffer (pH 6.2) were all made in this laboratory as previously recommended (2) except that bovalbumin was used in a final concentration of 0.5% instead of 1.0%. Phosphate-buffered saline (PBS), pH 7.2, was used as described (5) . (Both the HEPES and the dextran sulfate were from Nutritional Biochemicals Co., Cleveland, Ohio.)
Trypsin, lyophilized (Difco) or 3x crystalline trypsin, 100 mg/ampoule (lyophilized; Nutritional Biochemicals Co.) was used for treatment of the red cells.
Human blood was collected from five volunteers as a source of fresh cells and was mixed with an equal volume of Alsever's solution. In addition, three units of packed red cells were obtained from the Badger Regional Blood Center, American National Red Cross, Madison, Wis., on the date of expiration for transfusion purposes (21 days after collection). The cells were held at 4 C in the anticoagulant used for collection until trypsinization. All were Rh-positive cells except one of the units from the blood bank.
Newly hatched 2-day-old chickens' blood was collected in Alsever's solution on a weekly basis. These cells were washed three times in DGV immediately following the bleeding. They were then suspended at 10% concentration and held at 4 C in DGV. The previously cited paper (1), reporting trypsin treatment of cells, used crystalline trypsin at the rate of 1 mg for each ml of a 0.5% red blood cell suspension in PBS. We found working at that cell concentration (0.5%) inconvenient because large volumes had to be handled for washings. Preliminary studies showed no appreciable difference in effect, using 1 mg of trypsin/ml of cell concentrations at 0.5, 1.5, 3.0, 6.0, and 10%. We therefore used a 10% cell concentration throughout these studies.
Since trypsin (Difco) is a readily obtainable type of trypsin, studies were undertaken to evaluate this material. However, this introduced another problem, in that the activity of this material is standardized in terms of proteolytic activity rather than in milligrams of purified trypsin. Tests using the reconstituted trypsin undiluted, 1:2, 1:4, 1:8, and 1:16, at a ratio of 0.1 ml/ml of 10% cells showed that the first three dilutions gave essentially the same effect as the crystalline trypsin. Greater dilutions resulted in reduced antigen titers. To use the most effective concentration which might be expected to give minimal cell damage, the 1:4 dilution was chosen.
The trypsinization procedure was as follows. (i) Erythrocytes were washed three times in PBS by centrifuging at 600 x g in a 165-mm centrifuge head.
(ii) Concentration was adjusted to 10% by reading the packed-cell volume and adding PBS. (iii) Either 0.1 ml of crystalline trypsin aqueous solution containing 10 mg/ml or 0.1 ml of a 1:4 dilution of trypsin in water for each milliliter of cells was added. (iv) Incubation was at room temperature for 1 hr after mixing by gently inverting the tube. (v) The trypsinized cells were washed in PBS as in step i, and the cells were made to a 10% final concentration and stored at 4 C until used.
The procedure using newly hatched chicken erythrocytes was similar to that previously described (2) . For the procedure with trypsinized human cells, two changes were introduced. The cell concentration was increased to 0.3%, and the final incubation of the tests after adding cells was at 37 C. These changes were made since agglutination patterns were observed to be best at these values. Antigen titers run simultaneously at 4 C, room temperature, and 37 C showed no difference in levels of sensitivity, but the settling patterns of the cells were best at 37 C.
Microtitration U-plates were used throughout all tests.
RESULTS
Freshly drawn human erythrocytes of each blood type collected in Alsever's solution were washed and treated with trypsin as described. Freshly drawn cells from newly hatched chickens were tested both with and without trypsin treatment. As shown in Table 1 , trypsin treatment had no effect upon the chicken cells, whereas in each case the trypsinized human cells showed antigen titers equal to or greater than the chicken cell titer. Later tests using another source of fresh type 0, Rhpositive cells and three units of outdated type 0 blood, all 21 days old from the blood bank, showed similar results. All of the freshly drawn human cells could be held at 4 C in Alsever's solution for a minimum of 4 weeks after collection. During the first 3 weeks, these cells could be trypsin-treated and held for 3 to 5 days be- Another potential problem in using human cells is the possibility of cold agglutinins interfering with the test. As reported above, viral agglutination patterns were best at 37 C, and the antigen titers were essentially the same at 4 C, room temperature, and 37 C. It seemed likely that the use of incubation at 37 C after addition of the indicator cells to the plates would avoid this problem; however, to test the system, we obtained six sera from the Immunology Section with known cold agglutinin titers ranging from 1: 16 through 1: 4,096. The only serum that showed any nonspecific agglutinin was one with a cold-agglutinin titer of 1:4,096, and that could be removed by adsorption at 4 C, but not at 37 C. (Table 5 ). The use of types A, B, or AB, however, would offer no advantage and would lengthen the processing time necessary, since adsorption would be needed.
DISCUSSION
One difficulty in working with human type 0 cells is the possibility of interference by cold agglutinins. This problem is eliminated by incubation at 37 C for the final incubation phase of the test.
A recent paper (8) reported the hemagglutination by rubella virus of red cells from a number of species previously reported not to be usable for rubella testing. Among these was a human type 0, which gave titers slightly lower than newly hatched chicken cells. None were trypsin-modified. A more recent paper expanded upon the use of human 0 cells (7) . In our experience, only one of eight human bloods showed any demonstrable hemagglutination with rubella antigen without trypsin modification, and this showed a titer eightfold lower than chicken cells. All eight human cells worked equally well following trypsinization. It is possible that human cells from certain individuals may be usable with no treatment, but, with this trypsin modification, we have had uniformly good results with all cells tested.
Most procedures recommend the use of microtiter V-plates for the rubella hemagglutination-inhibition test. We recommend V-plates for this procedure as well since on occasion tests run with U-plates were difficult to read and showed poor endpoints.
